109 related articles for article (PubMed ID: 1000706)
21. [Current treatment of Parkinsonian syndrome].
Lechner H; Bertha G; Ott E
Med Welt; 1980 Oct; 31(40):1444-6. PubMed ID: 7464500
[No Abstract] [Full Text] [Related]
22. [Psychological status of patients with Parkinsonism during treatment with amantadine hydrochloride and L-Dopa].
Ferraris M
Minerva Med; 1971 Oct; 62(82):3971-3. PubMed ID: 5125056
[No Abstract] [Full Text] [Related]
23. [Results after 3 to 5 years of treatment of 219 cases of Parkinson's syndrome treated by L-Dopa and an L-Dopa -decarboxylase inhibitor combination].
Boudin G; Pepin B; Guillard A; Godlewski S; Fabiani JM; Haguenau M
Rev Neurol (Paris); 1974; 130(7-8):273-84. PubMed ID: 4217929
[No Abstract] [Full Text] [Related]
24. [Review of problems in the treatment of the parkinsonian syndrome with L-dopa].
Piccirilli M; Quartesan R
Clin Ter; 1976 Mar; 76(5):467-77. PubMed ID: 991553
[No Abstract] [Full Text] [Related]
25. [L dopa and mental disorders].
Castaigne P
Int J Neurol; 1975; 10(1-4):178-85. PubMed ID: 1181309
[No Abstract] [Full Text] [Related]
26. The treatment of parkinsonism.
Godwin-Austen R
Practitioner; 1975 Oct; 215(1288):445-51. PubMed ID: 1202468
[No Abstract] [Full Text] [Related]
27. Twenty-five years of amantadine therapy in Parkinson's disease.
Danielczyk W
J Neural Transm Suppl; 1995; 46():399-405. PubMed ID: 8821075
[TBL] [Abstract][Full Text] [Related]
28. Therapy of neurologic disorders in the elderly.
Mancall EL; Covington TR; Alonso RJ
Hosp Pract (Off Ed); 1984 Oct; 19(10):106E, 106I, 106L passim. PubMed ID: 6434551
[No Abstract] [Full Text] [Related]
29. Effect of amantadine (Viregyt-K) on extrapyramidal symptoms of parkinsonian patients.
Boczán G
Ther Hung; 1974; 22(4):147-53. PubMed ID: 4465958
[No Abstract] [Full Text] [Related]
30. [New aspects of chronic occupational manganese poisoning].
Schunk W
Z Gesamte Inn Med; 1982 Mar; 37(6):177-80. PubMed ID: 7090458
[TBL] [Abstract][Full Text] [Related]
31. [The therapeutic effectiveness of amantadine (midantan) in parkinsonism syndromes].
Kiseleva AM; Zlydnikov DM; Mazhinskaia VP; Lebedeva VK; Zakharova NG
Zh Nevropatol Psikhiatr Im S S Korsakova; 1973; 73(4):530-4. PubMed ID: 4705408
[No Abstract] [Full Text] [Related]
32. [Antiparkinsonian drugs (author's transl)].
Ando K
No To Shinkei; 1980 Aug; 32(8):743-53. PubMed ID: 7008813
[No Abstract] [Full Text] [Related]
33. [Clinical and biochemical considerations on depressive states occuring during parkinsonian syndrome treated by L-Dopa].
Gisselmann A; Boudry C; Marin A; Ballivet J
Encephale; 1976; 2(2):105-13. PubMed ID: 1278088
[TBL] [Abstract][Full Text] [Related]
34. Levetiracetam potentiates the antidyskinetic action of amantadine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson's disease.
Hill MP; Ravenscroft P; Bezard E; Crossman AR; Brotchie JM; Michel A; Grimée R; Klitgaard H
J Pharmacol Exp Ther; 2004 Jul; 310(1):386-94. PubMed ID: 15004218
[TBL] [Abstract][Full Text] [Related]
35. Electroretinogram in parkinsonism and effects of L-DOPA.
Filipová M; Terziivanov D; Balík J; Janků I; Filip V; Stika L; Krejcová H
Act Nerv Super (Praha); 1981 Dec; 23(4):301-2. PubMed ID: 7336872
[No Abstract] [Full Text] [Related]
36. A simple rodent assay for the in vivo identification of agents with potential to reduce levodopa-induced dyskinesia in Parkinson's disease.
Johnston TH; Lee J; Gomez-Ramirez J; Fox SH; Brotchie JM
Exp Neurol; 2005 Feb; 191(2):243-50. PubMed ID: 15649479
[TBL] [Abstract][Full Text] [Related]
37. [L-dopa + peripheral decarboxylase antagonist].
Wiesel FA
Lakartidningen; 1975 Oct; 72(43):4173. PubMed ID: 1177632
[No Abstract] [Full Text] [Related]
38. Nosological concept of juvenile parkinsonism with reference to the dopa-responsive syndrome.
Yokochi M
Adv Neurol; 1993; 60():548-52. PubMed ID: 8420189
[No Abstract] [Full Text] [Related]
39. Pharmacotherapy: problems and practices.
Muenter MD
Clin Neuropharmacol; 1986; 9 Suppl 1():S23-36. PubMed ID: 3708606
[TBL] [Abstract][Full Text] [Related]
40. Dopa-responsive dystonia. Delineation of the clinical syndrome and clues to pathogenesis.
Nygaard TG
Adv Neurol; 1993; 60():577-85. PubMed ID: 8420194
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
